摘要: Non-small-cell lung cancer (NSCLC) accounts for 70%–80% of all cancers and represents three the four histological subgroups (epidermoid or squamous cancer, adenocarcinoma, large cell anaplastic carcinoma). Surgical resection is treatment choice localised NSCLC but only 10%–15% patients are resectable at time diagnosis. Even in those with operable disease, 5-year survival rates range from 28%–40%. The need improved therefore clear.
springer.com
sci-hub.st 参考文章(26)
Jean Klastersky, E. Longeval, Robert De Jager, High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium) Cancer treatment reports. ,vol. 64, pp. 1341- 1346 ,(1980)
Zbigniew Petrovich, Maimu Ohanian, James Cox, Clinical research on the treatment of locally advanced lung cancer.Final report of VALG protocol 13 limited Cancer. ,vol. 42, pp. 1129- 1134 ,(1978) , 10.1002/1097-0142(197809)42:3<1129::AID-CNCR2820420315>3.0.CO;2-F
R.B. Livingston, Combination chemotherapy of bronchogenic carcinoma I. Non-oat cell Cancer Treatment Reviews. ,vol. 4, pp. 153- 165 ,(1977) , 10.1016/S0305-7372(77)80022-4
Margaret F Spittle, Haydn Bush, Sally E James, Kurt Hellmann D.M, Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus International Journal of Radiation Oncology Biology Physics. ,vol. 5, pp. 1649- 1651 ,(1979) , 10.1016/0360-3016(79)90790-9
D. Byar, Y. Kenis, J.G. Van Andel, M. de Jong, P. Laval, L. Marion, J.E. Couette, J. Longueville, Results of a E.O.R.T.C. Randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: prognostic factors and treatment results. European Journal of Cancer. ,vol. 14, pp. 919- 930 ,(1978) , 10.1016/0014-2964(78)90018-X
Emile Longeval, Jean Klastersky, Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) Cancer. ,vol. 50, pp. 2751- 2756 ,(1982) , 10.1002/1097-0142(19821215)50:12<2751::AID-CNCR2820501210>3.0.CO;2-3
Sewa S. Legha, Franco M. Muggia, Stephen K. Carter, Adjuvant chemotherapy in lung cancer.Review and prospects Cancer. ,vol. 39, pp. 1415- 1424 ,(1977) , 10.1002/1097-0142(197704)39:4<1415::AID-CNCR2820390410>3.0.CO;2-O
Robert B. Livingston, William H. Fee, Lawrence H. Einhorn, Michael A. Burgess, Emil J. Freireich, Jeffrey A. Gottlieb, Mark O. Farber, Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients Cancer. ,vol. 37, pp. 1237- 1242 ,(1976) , 10.1002/1097-0142(197603)37:3<1237::AID-CNCR2820370302>3.0.CO;2-Z
Robert L. Palmer, Paul M. Kroening, Comparison of low dose radiation therapy alone or combined with procarbazine (NSC‐77213) for unresectable epidermoid carcinoma of the lung, stage t3, N1, N2, or ML Cancer. ,vol. 42, pp. 424- 428 ,(1978) , 10.1002/1097-0142(197808)42:2<424::AID-CNCR2820420207>3.0.CO;2-F
RICHARD J. GRALLA, Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules Annals of Internal Medicine. ,vol. 95, pp. 414- 420 ,(1981) , 10.7326/0003-4819-95-4-414